Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  osteosarcoma/malignant fibrous histiocytoma of bone
Stage/Subtype:  osteosarcoma/malignant fibrous histiocytoma of bone
Trial Type:  Treatment
Results 1-25 of 32 for your search:
Start Over
Hypofractionated or Single Dose Image-Guided Radiation Therapy in Treating Patients with Metastatic Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 10-154, NCI-2010-02150, NCT01223248
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Aerosolized Aldesleukin in Treating Patients with Lung Metastases
Phase: Phase II, Phase I
Type: Treatment
Age: 12 and over
Trial IDs: 2010-0700, NCI-2012-00788, NCT01590069
Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
Phase: Phase II, Phase I
Type: Treatment
Age: 15 and over
Trial IDs: 2012-0952, NCI-2013-02267, ONC-2012-66, NCT01833520
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 21 years
Trial IDs: ABI-007-PST-001, NCI-2015-00737, NCT01962103
OKT3/Humanized 3F8 Bispecific Antibody-Activated T Lymphocytes, Aldesleukin, and Sargramostim in Treating Younger Patients with GD2-Positive Metastatic, Recurrent or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 moths to 29 years
Trial IDs: 2013-171, NCI-2014-01149, 1403012875, NCT02173093
Nivolumab with or without Ipilimumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors or Sarcomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: ADVL1412, NCI-2014-01222, NCT02304458
Alisertib in Treating Patients with Advanced or Metastatic Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A091102, NCI-2012-01991, CALGB-A091102, CDR0000737403, NCT01653028
Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 and over
Trial IDs: AWACMOS1102, NCI-2013-01371, ACORN AWACMOS1102, NCT01759303
Hypofractionated Stereotactic Radiation Therapy in Treating Younger Patients with Metastatic Sarcomas of Bony Sites
Phase: Phase II
Type: Treatment
Age: Greater than 3 to less than or equal to 40
Trial IDs: J1367, NCI-2013-02433, NA_00070109, NCT01763970
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, CIR00008429, CIR00009228, NA_00076243, NA_00076243 / CIR00009228, NCT01804634
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 18
Trial IDs: 116731, NCI-2015-00058, NCT01956669
Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients with Metastatic Sarcoma Stable on Chemotherapy
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201309108, NCI-2013-01842, NCT01986829
A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SARC024, NCI-2014-02023, NCT02048371
Eribulin Mesylate in Treating Patients with Recurrent or Refractory Osteosarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 to 49
Trial IDs: AOST1322, NCI-2014-00621, COG-AOST1322, NCT02097238
Cabozantinib-s-malate in Treating Patients with Relapsed Osteosarcoma or Ewing Sarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 and over
Trial IDs: CABONE, NCI-2014-01927, 9620, NCT02243605
A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Phase: Phase II
Type: Treatment
Age: 12 and over
Trial IDs: SARC028, NCI-2015-00320, NCT02301039
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients with Metastatic Soft Tissue and Bone Sarcomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 14S03, NCI-2014-02583, STU00200112, NCT02357810
Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-027, NCI-2014-01952, REN13120042, UPCI #10-027, NCT01345539
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
HER2-Specific T Cells in Treating Patients With HER2-Positive Refractory or Metastatic Sarcoma
Phase: Phase I
Type: Treatment
Age: Not specified
Trial IDs: HEROS, NCI-2012-00634, NCT00902044
Dasatinib and Ipilimumab in Treating Patients with Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-083, NCI-2012-01165, CDR0000737378, 9172, NCT01643278
Monoclonal Antibody 3F8 and Aldesleukin in Treating Patients with High-Risk Neuroblastoma and Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months and over
Trial IDs: 12-116, NCI-2012-01383, NCT01662804
Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 20 years
Trial IDs: SPOC-2012-001, NCI-2014-02681, NCT02013336
Start Over